Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Acta Academiae Medicinae Sinicae ; (6): 607-610, 2016.
Artigo em Inglês | WPRIM | ID: wpr-277932

RESUMO

Implant-based breast reconstruction is the most common choice in breast cancer patients. Recently,the acellular dermal matrix (ADM) technique has been widely used in implant-based breast reconstruction in the western countries. This article briefly reviews the biological characteristics,history,types,surgical techniques,and postoperative complications of ADM.


Assuntos
Feminino , Humanos , Derme Acelular , Implante Mamário , Implantes de Mama , Neoplasias da Mama , Cirurgia Geral , Mastectomia , Complicações Pós-Operatórias
2.
Journal of Southern Medical University ; (12): 1047-1050, 2011.
Artigo em Chinês | WPRIM | ID: wpr-235200

RESUMO

<p><b>OBJECTIVE</b>To evaluate the value of cardiac troponin I (CTnI) measurement in predicting anthracycline-induced cardiotoxicity in patients with breast cancer.</p><p><b>METHODS</b>This study was conducted among 186 breast cancer patients receiving anthracycline-based chemotherapy. Serum cTnI concentrations before and after each cycle of the chemotherapy and the left ventricular ejection fraction (LVEF) before and at the 2nd, 4th and 6th months of the treatment were recorded. According to serum cTnI concentration, the patients were divided into CTnI+ group (with serum CTnI concentration of no less than 0.1 ng/ml, n=60) and CTnI- (<0.1 ng/ml) group (n=126).</p><p><b>RESULTS</b>No patients in this series experienced cardiac heart failure (CHF). The number of patients with a LVEF reduction by over 10% from the baseline was 16 (26.7%) in CTnI+ group, as compared to 7 (5.6%) in CTnI- group, showing a significant difference between the two groups (P<0.01).</p><p><b>CONCLUSION</b>CTnI can be a useful marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.</p>


Assuntos
Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Adulto Jovem , Antraciclinas , Usos Terapêuticos , Antibióticos Antineoplásicos , Usos Terapêuticos , Biomarcadores , Sangue , Neoplasias da Mama , Tratamento Farmacológico , Cardiotoxinas , Miocárdio , Metabolismo , Troponina I , Sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA